The MPO study: Just a European HEMO study or something very different?

Blood Purification

Volumn 26, Issue 1, 2008, Pages 100-104

  Locatelli, Francesco ^a   Gauly, Adelheid ^b   Czekalski, Stanislaw ^c   Hannedouche, Thierry ^d   Jacobson, Stefan H ^e   Loureiro, Alfredo ^f   Martin Malo, Alejandro ^g   Papadimitriou, Menelaos ^h   Passlick Deetjen, Jutta ^b   Ronco, Claudio ⁱ   Vanholder, Raymond ^j   Wizemann, Volker ^k  

^a A MANZONI HOSPITAL   (Italy)

^b FRESENIUS MEDICAL CARE   (Germany)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e DANDERYD HOSPITAL   (Sweden)

^f PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h Aristotle University of Thessaloniki   (Greece)

ⁱ SAN BORTOLO HOSPITAL   (Italy)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k Georg Haas Dialysis Centre   (Germany)

more..

Author keywords

Hemodialysis; Membrane permeability; Mortality; Serum albumin

Indexed keywords

SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; EUROPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; INTERVENTION STUDY; MALNUTRITION; MEMBRANE; MEMBRANE PERMEABILITY; METHODOLOGY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SELECTION; POPULATION; PRIORITY JOURNAL; RISK; RISK FACTOR; SURVIVAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIAS (EPIDEMIOLOGY); HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 38049054805     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110574     Document Type: Conference Paper

References (28)

1. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996;50:1293-1302.
2. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997;52:1096-1101.
3. Schiffl H, Fischer R, Lang SM, Mangel E: Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant 2000;15:840-845.
4. Hartmann J, Fricke H, Schiffl H: Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997;30:366-373.
5. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA: High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995;5:1703-1708.
6. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J: Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19:2570-2575.
7. Locatelli F, Manzoni C: Treatment modalities in comparison: when do clinical differences emerge? Nephrol Dial Transplant 2000;15(suppl 1):29-35.
8. Hornberger JC, Chernew M, Petersen J, Garber AM: A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992;3:1227-1237.
9. Bloembergen WE, Hakim RM, Stannard DC, Held PJ, Wolfe RA, Agodoa LY, Port FK: Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999;33:1-10.
10. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
11. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003;14:3251-3263.
12. Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK, Kaysen GA, Levey AS, Sarnak MJ, Schwab SJ: Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Am J Kidney Dis 2006;47:131-138.
13. Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, Orzol SM, Held PJ: Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 2001;37:276-286.
14. Chauveau P, Nguyen H, Combe C, Chene G, Azar R, Cano N, Canaud B, Fouque D, Laville M, Leverve X, Roth H, Aparicio M: Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005;45:565-571.
15. Krane V, Krieter DH, Olschewski M, Marz W, Mann JF, Ritz E, Wanner C: Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 2007;49:267-275.
16. Pifer TB, McCullough KP, Port FK, Goodkin DA, Maroni BJ, Held PJ, Young EW: Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002;62:2238-2245.
17. Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R: The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. J Nephrol 1999;12:85-88.
18. Afsar B, Sezer S, Arat Z, Tutal E, Ozdemir FN, Haberal M: Reliability of mini nutritional assessment in hemodialysis compared with subjective global assessment. J Ren Nutr 2006;16:277-282.
19. Kaysen GA, Stevenson FT, Depner TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997;29:658-668.
20. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911.
21. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK: Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 2002;40:721-727.
22. Joki N, Hase H, Tanaka Y, Takahashi Y, Saijyo T, Ishikawa H, Inishi Y, Imamura Y, Hara H, Tsunoda T, Nakamura M: Relationship between serum albumin level before initiating haemodialysis and angiographic severity of coronary atherosclerosis in endstage renal disease patients. Nephrol Dial Transplant 2006;21:1633-1639.
23. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006;69:1081-1087.
24. Dwyer JT, Larive B, Leung J, Rocco MV, Greene T, Burrowes J, Chertow GM, Cockram DB, Chumlea WC, Daugirdas J, Frydrych A, Kusek JW: Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Kidney Int 2005;68:1766-1776.
25. The DOPPS Report 2004: http://www.dopps.org/pdfs/dopps_report_2004.pdf
26. Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, Levin NW, Schulman G, Eknoyan G: Design and statistical issues of the hemodialysis (HEMO) Study. Control Clin Trials 2000;21:502-525.
27. 2-microglobulin. The Hemodialysis (HEMO) Study Group. J Am Soc Nephrol 1999;10:117-127.
28. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.